Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2011-11-17 17:08:11
Reporting Period:
Filing Date:
Accepted Time:
2011-11-17 17:08:11
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1097264 Allos Therapeutics Inc ALTH Pharmaceutical Preparations (2834) 541655029
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1290061 C David Clark 11080 Circlepoint Road
Suite 200
Westminster CO 80020
Vp, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-11-15 5,438 $1.45 116,288 No 4 S Direct
Common Stock Disposition 2011-11-16 125 $1.43 116,163 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
  1. These shares are being sold pursuant to a 10b5-1 plan for David C. Clark in order to cover the withholding tax and other costs associated with such sale (i.e., wire fees, commission or interest) in connection with the vesting of restricted stock units on October 20, 2011. The delivery of shares was delayed until November 14, 2011, due to legal / regulatory restrictions applicable to the Company.
  2. The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.43 to $1.475. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.